The Council’s Regine Struk-Ware will discuss male contraception during this free NIH webinar. Attendees will learn about a first-of-its-kind male contraceptive hormonal gel, Nestorone®/Testosterone (NES/T), co-developed by the NICHD and Population Council through the Contraceptive Clinical Trials Network (CCTN). This topical, daily self-applied transdermal gel is designed to provide full sperm suppression within 8-12 weeks and be reversible after 12-16 weeks of ending application. This presentation will showcase NES/T gel as an innovative, user-controlled option for male contraception.
To attend the webinar, please register here.